Several indolocarbazole derivatives have progressed to phase II/III clinical trials or have been approved as clinically effective drugs for various cancers, including being potent inhibitors of protein kinase and topoisomerase-1, such as rebeccamycin and staurosporine [31]. The gene discussed is WEE1; the disease is cancer.